Hetrombopag shows high response rates and good tolerability in paediatric immune thrombocytopenia, supporting its use as an ...
Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...
Sanofi SNY announced that the FDA has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adult patients who have had ...
Ouro Medicines, a clinical stage biotechnology company developing immune reset therapeutics for people living with chronic, ...
Findings showed 23% of patients treated with rilzabrutinib achieved durable platelet response compared with none of the patients receiving placebo. The Food and Drug Administration (FDA) has approved ...
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today highlighted the ...
Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...
ITP does not increase the risk of getting or having severe COVID-19. COVID-19 infection can cause thrombocytopenia, even in those without ITP history. ITP may develop as a rare side effect of the ...
Please provide your email address to receive an email when new articles are posted on . A 65-year-old male presented for his annual exam. The medical assistant (MA) checking the patient in remarked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results